王 洁,阿祥仁,韦亚妹

肝细胞癌（HCC）是全世界癌症相关死亡原因的第四大原因，且肝细胞癌的总体预后很差。HBV（乙型肝炎病毒）相关性肝癌居于其他原因引起的肝癌（例如：酒精性、自身免疫性相关性肝癌）的首位。近年来，关于HBV相关性肝癌的诊断标志物研究不断，均致力于发现特异性及灵敏性都高的诊断标记物以及诊断HBV相关肝癌的标志物联合诊断的特异性与灵敏性。本文旨在总结HBV相关肝癌的传统及最新血清诊断标记物（不包括基因组学标志物），探讨HBV相关性肝癌血清标记物联合检测提高HBV相关性肝癌的早期诊断效用。

乙型肝炎病毒性肝癌；肝癌；血清诊断标记物；联合检测诊断

[1] Nicole E R.Changing Epidemiology of Hepatocellular Carcinoma Within the United States and Worldwide[J].Surgical Oncology Clinics of North America,2024. [2] Leila K,Zahra Rostami G,Arsalan G,et al.A state-of-the-art review on the NRF2 in Hepatitis virus-associated liver cancer[J].Cell Communication and Signaling,2023. [3] Shi J F,Cao M,Wang Y,et al.Is it possible to halve the incidence of liver cancer in China by 2050?[J].Int J Cancer,2021,148(5):1051-1065. [4] Xin H,Ronggao C,Qiang W,et al.The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma:Where Are We?[J].International Journal of Biological Sciences,2022. [5] 杜江标,崔英,梁新强,等.多种肿瘤标志物对原发性肝癌的诊断价值%J 广西医科大学学报[J].2020,37(12):2210-2214. [6] Norman J S,Li P J,Kotwani P,et al.AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation[J].J Hepatol,2023,79(6):1469-1477. [7] 黄建芳,王怡,陈怡,等.肿瘤标志物 PIVKA-Ⅱ、AFP 联合纤溶二项 DD、FDP 检测在原发性肝癌诊断中的应用价值研究%J 中国卫生检验杂志[J].2023,33(20):2520-2523. [8] 章希文,高琳,李飞,等.NLR、PIVKA-Ⅱ和 AFP 联合检测在原发性肝癌中的诊断价值%J 中国现代医生[J].2023,61(32):63-66+70. [9] Yuanquan S,Xiuqin W,Cui-Cui P,et al.An Efficient Nomogram for Discriminating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma:A Retrospective Study[J].Frontiers in Oncology,2022. [10] Yimin H,Ruoxi R,Chaoqi Y,et al.The diagnostic and prognostic implications of PRKRA expression in HBV-related hepatocellular carcinoma[J].Infectious Agents and Cancer,2022. [11] Jianing F,Hao W.Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation[J].Annual Review of Immunology,2023. [12] Fei L,Yanan Z,Yingxin P,et al.NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma[J].Cancer Letters,2021. [13] Jawed A S,Ramesh P,Parvez K,et al.Pathophysiological role of growth differentiation factor 15(GDF15)in obesity,cancer,and cachexia[J].Cytokine&Growth Factor Reviews,2022. [14] Juanjuan C,Dongling T,Xu C,et al.Evaluation of Serum GDF15,AFP,and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma[J].Laboratory Medicine,2020. [15] 陈文亮,徐细明.肝癌早期诊断标志物的研究新进展%J 中国医药导报[J].2023,20(01):40-44. [16] Zhuolun S,Wei C,Dipti A,et al.Osteopontin Takes Center Stage in Chronic Liver Disease[J].Hepatology,2021. [17] Min T,Cheng G,Mucun S,et al.Effective delivery of osteopontin small interference RNA using exosomes suppresses liver fibrosis via TGF-β1 signaling[J].Frontiers in Pharmacology,2022. [18] Chiao-Fang T,Han Chieh W,Ih‐Jen S,et al.Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma[J].Viruses,2020. [19] Mai Huong Thi N,Han Yin J,Yung Che K,et al.The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas:Stemness-Related Properties and Drug Resistance[J].International Journal of Molecular Sciences,2021. [20] Tian K,Deng Y,Li Z,et al.AKR1B10 inhibits the proliferation and metastasis of hepatocellular carcinoma cells by regulating the PI3K/AKT pathway[J].Oncol Lett,2024,27(1):18. [21] Kim S Y,Shen Q,Son K,et al.SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer[J].Oncogene,2021,40(28):4652-4662. [22] 任晨然,郭敏,王涛,等.原发性肝癌血清标志物:机会与挑战%J 中南医学科学杂志[J].2024,52(03):313-317. [23] Kozumi K,Kodama T,Murai H,et al.Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis[J].Hepatology,2021,74(5):2452-2466. [24] Kramvis A,Chang K M,Dandri M,et al.A roadmap for serum biomarkers for hepatitis B virus:current status and future outlook[J].Nat Rev Gastroenterol Hepatol,2022,19(11):727-745.

点击下载PDF